Polyclonal immunoglobulin for cutaneous treatment of infections with Staphylococcus

With support of the NADP Vouchers (a Value Proposition Voucher and a Lead Development Voucher) we have developed a sprayable skin gel containing a cocktail of antibodies that are directed against various virulence factors of Staphylococcus aureus. The antibody shows efficacy against a broad spectrum of Staphylococcus strains, also against multi-resistant strains. The antibody can be used as alternative or adjunctive therapy to standard antibiotics.

We have elaborated a regulatory strategy for development of a human as well as a veterinary therapeutic skin product until market release and discussed our strategy successfully with the Innovation Task Force Office of the European Medicines Agency. This research has led to further financing (€ 200.000) by a German Business Angel. In addition, a company was started to bring the research further: Doderm GmbH.

Dr. Beatrix Förster, UMC Utrecht